NEXI (NEXI) Stock Price & Analysis
NEXI (NEXI) rose 0.00% to USD 0 as of June 10, 2026 at 04:34 UTC, according to Nexqual real-time market data.
NEXI last closed at USD 0; the session ranged USD 0–0 on volume of 100 shares. Market capitalization is $139, with a 52-week range of USD 0–1.01 (PNK). Source: Nexqual, June 10, 2026 at 04:34 UTC.
Key Statistics (as of June 10, 2026 at 04:34 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 1.01 |
| Volume | 100 shares |
| Market Cap | $139 |
| Exchange | PNK |
Technical Analysis (NEXI)
Nexqual's technical model rates NEXI "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 04:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (NEXI)
Wall Street analysts rate NEXI "None", per Nexqual as of June 10, 2026 at 04:34 UTC.
| Consensus Rating | None |
|---|
Earnings (NEXI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-06-30 | USD -7.25 vs est -7.25 ▲ beat |
| 2023-03-31 | USD -9.25 vs est -11.63 ▲ beat |
| 2022-12-31 | USD -16.25 vs est -12.88 ▼ miss |
| 2022-09-30 | USD -15 vs est -17.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:34 UTC.
Financials & Fundamentals (NEXI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -232.97% |
| Current Ratio | 0.66 |
| Total Cash | $2.42M |
| Total Debt | $0 |
| Free Cash Flow | $-7.10M |
Source: Nexqual, June 10, 2026 at 04:34 UTC.
Financial Health Score (NEXI)
Nexqual rates NEXI's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Critical — ROE -233%, ROA -72.7% |
Ownership (NEXI)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 1.39M |
| Float | 1.18M |
| Short % of Float | +1.30% |
Source: Nexqual, June 10, 2026 at 04:34 UTC.
Leadership (NEXI)
NEXI is led by Daniel P. Bednarik, Senior Vice President of Molecular Engineering & Protein Design, per Nexqual as of June 10, 2026 at 04:34 UTC.
| Senior Vice President of Molecular Engineering & Protein Design | Daniel P. Bednarik |
|---|---|
| Senior Vice President of Corporate Affairs | Chad Rubin |
| Senior Vice President of Translational Science | Jack A. Ragheb |
Major Backers & Investors (NEXI)
Notable institutional backers of NEXI include Raymond James & Associates, Inc., according to Nexqual as of June 10, 2026 at 04:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Raymond James & Associates, Inc. | 0.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.86% |
Source: Nexqual, June 10, 2026 at 04:34 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PBLA | Panbela Therapeutics, Inc. | USD 0.01 | ▲ 0% |
| FIEE | FiEE, Inc | USD 4.03 | ▼ 8.62% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| CING | Cingulate Inc. | USD 4.65 | ▲ 3.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:34 UTC. This page is informational and not investment advice.